CPRX - CATALYST PHARMACEUTICALS, INC.

24.69
0.770   3.119%

Share volume: 1,026,073
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$23.92
0.77
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
43%
Profitability 54%
Dept financing 4%
Liquidity 75%
Performance 34%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.39%
1 Month
3.26%
3 Months
4.93%
6 Months
21.69%
1 Year
12.79%
2 Year
51.75%
Key data
Stock price
$24.69
P/E Ratio 
13.39
DAY RANGE
$23.73 - $24.80
EPS 
$1.75
52 WEEK RANGE
$19.05 - $26.58
52 WEEK CHANGE
$13.94
MARKET CAP 
2.869 B
YIELD 
N/A
SHARES OUTSTANDING 
122.124 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.84
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,532,277
AVERAGE 30 VOLUME 
$1,346,445
Company detail
CEO: Patrick J. McEnany
Region: US
Website: catalystpharma.com
Employees: 80
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Catalyst Pharmaceuticals, Inc. focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and Ruzurgi.

Recent news